Skip to main content
. 2014 Jan 16;63(2):585–595. doi: 10.2337/db13-0666

Figure 6.

Figure 6

Pancreas-specific deletion of SH2B1 decreases islet mass, pancreatic insulin content, and islet function. Male mice fed an HFD (60% fat) for 10–12 weeks. A: H-E staining of pancreas sections. B: Pancreatic sections were immunostained with anti-insulin or anti-glucagon antibodies. C: Islet area was quantified and normalized to pancreatic section area. Control: n = 10; PKO: n = 11. D: Pancreatic insulin content in fasted (16 h) male mice was measured and normalized to pancreas weights. Control: n = 8; PKO: n = 6. E and F: Islet cell apoptosis measured by TUNEL assays. Control: n = 6; PKO: n = 5. G: Islets were isolated from SH2B1f/f (control, n = 3) and PKO (n = 4) male mice (14–16 weeks) treated with cytokines (IL-1β: 1 ng/mL; TNF-α: 5 ng/mL; and INF-γ: 5 ng/mL) for 16–17 h. Apoptosis was analyzed using TUNEL assays. TUNEL-positive cells were normalized to total islet cells. H and I: Pancreatic sections were costained with anti-Ki67 and anti-insulin antibodies. Control: n = 8; PKO: n = 11. J–L: Males (9–10 weeks) were fed an HFD (45% fat) for 1 week and then injected with STZ (25 mg/kg) daily for 5 days. J: Blood glucose was monitored weekly. Control: n = 29; PKO: n = 16. K: Plasma insulin levels 5 weeks after STZ treatment. Control: n = 28; PKO: n = 16. L: Pancreatic insulin content 5 weeks after STZ treatment. Control: n = 25; PKO: n = 11. Data are means ± SE. *P < 0.05. Con, control.